Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials
Background: Hyperuricemia is a risk factor for the development of hypertension and is comorbid in many hypertensive patients. According to Japanese hypertension management guidelines published in 2019, a target serum uric acid level of ≤6.0 mg/dL is recommended in hypertensive patients with gout or...
| Автори: | , , , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Taylor & Francis Group
2021-11-01
|
| Серія: | Clinical and Experimental Hypertension |
| Предмети: | |
| Онлайн доступ: | http://dx.doi.org/10.1080/10641963.2021.1950752 |